Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Insights - The approval of the core product APL-1702 marks a new stage in the company's development, with significant commercial preparations already in place for its market launch [5] - APL-1702, branded as 希维她®/CEVIRA®, is a pioneering photodynamic therapy product aimed at treating patients with cervical intraepithelial neoplasia (CIN2), addressing a substantial unmet clinical need in non-invasive treatment options [6] - The company is actively pursuing international market opportunities, having received acceptance from the European Medicines Agency and reached an agreement with the FDA on the clinical design for U.S. market entry [5] Financial Performance - The company forecasts revenues of 277 million yuan in 2025, representing a year-on-year growth of 37.49%, driven by the commercialization of existing products [7] - The net profit attributable to the parent company is projected to be -419 million yuan for 2025, reflecting ongoing high R&D investments and preparations for new product commercialization [8] - Revenue projections for 2025-2027 are 277 million, 501 million, and 803 million yuan respectively, with net profits expected to improve from -419 million to -149 million yuan over the same period [8][10] Market Demand - There is a significant unmet clinical demand for non-invasive treatments for cervical intraepithelial neoplasia, with over 700,000 diagnosed HSIL patients in China, of which approximately 60% are CIN2 cases [6] - The World Health Organization's initiative to eliminate cervical cancer aligns with the company's goals, as China aims for a 90% treatment rate for cervical cancer and precancerous lesions by 2030 [6] Commercialization Strategy - The company is implementing a "Commercialization 2.0" strategy, which has shown effectiveness with continuous growth in generic drug sales [5] - The successful launch of APL-1702 is expected to significantly enhance the company's revenue, alongside the ongoing growth of its generic drug portfolio [8]

Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Insights - The approval of the core product APL-1702 marks a new stage in the company's development, with significant commercial preparations already in place for its market launch [5] - APL-1702, branded as 希维她®/CEVIRA®, is a pioneering photodynamic therapy product aimed at treating patients with cervical intraepithelial neoplasia (CIN2), addressing a substantial unmet clinical need for non-invasive treatment options [6] - The company is actively pursuing international market opportunities, having received acceptance from the European Medicines Agency and reached an agreement with the FDA on the clinical design for U.S. market entry [5] Summary by Sections Market Performance - The company's stock price is currently at 16.91 yuan, with a total market capitalization of 9.7 billion yuan and a 52-week price range of 7.22 to 17.66 yuan [1] Investment Highlights - The company reported a revenue of 277 million yuan for 2025, reflecting a year-on-year growth of 37.49%, driven by the commercialization of its products [7] - The net profit attributable to the parent company is projected to be -419 million yuan for 2025, primarily due to ongoing R&D investments and preparations for new product launches [7] - Revenue forecasts for 2025-2027 are 277 million, 501 million, and 803 million yuan respectively, with net profits expected to improve from -419 million to -149 million yuan over the same period [8] Financial Projections - The report predicts a significant increase in revenue growth rates, with 2025 expected to see a 37.5% increase, followed by 80.8% in 2026 and 60.3% in 2027 [10] - The earnings per share (EPS) are projected to improve from -0.73 yuan in 2025 to -0.26 yuan in 2027, indicating a potential turnaround in profitability as the core product gains market traction [8]